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Summary The direct detection and monitoring of anti-cancerdrugs in vivo by magnetic resonance spectroscopy (MRS) may lead to improved
anti-cancer strategies. 31P-MRS has been used to detect and quantify ifosfamide (IF) in vivo in GH3 prolactinomas and N-methyl-N-
nitrosourea (MNU)-induced mammary tumours in rats. The average concentration of IF in the GH3 prolactinoma over the first 2 h following a
dose of 250 mg kg-' i.v. was calculated to be 0.42 ,umol g-1 wet weight, with a half-life of elimination (t,,2) of 2-4 h. Carbogen (95% oxygen/5%
carbon dioxide) breathing increased the amount of IF taken up bythe GH3 prolactinoma by 50% (P<0.01) to 0.68,umol g-1 wetweight, although
t,,2 elimination rates were unchanged. IF was also detected in the liver in vivo, with a t,,c of about 1 h. Carbogen breathing did not affect the
maximum peak area (Cmax) orthe t,,2 in the liver. Most importantly, the carbogen-induced increase in IF uptake by the tumourcaused significant
growth delay at all time points in the GH3 tumour growth between day 5 and day 12 (P< 0.01) compared with IF alone. These findings show
that carbogen breathing has potential for increasing the efficacy of anti-cancer drugs. Isolated GH3 cells were sensitive to the parentdrug (IF)
in vitro (C~50= 1.3 ± 0.2 mM) suggesting that the GH3 cells may be either expressing P450 enzymes or are sensitive to the parent drug per se.
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Of the many anti-cancer agents that exist, only a few have been
monitored non-invasively by magnetic resonance spectroscopy
(MRS) (Malet Martino et al, 1992; Artemov et al, 1995; He et
al, 1995). This study was designed to take advantage of the non-
invasive technique of31P-MRS forpharmacokinetic studies ofifos-
famide (IF), an alkylating oxazaphosphorine drug and a structural
isomer of cyclophosphamide (Figure 1), which is widely used in
the treatment of soft-tissue sarcomas and paediatric malignancies
(Pinkerton and Pritchard, 1989; Pratt et al, 1989.) IF is a prodrug
that is metabolized in vivo to produce a range of therapeutically
active and potentially toxic metabolites (Sladek, 1988), and its
initial metabolism consists of two different pathways (Figure 1).
Firstly, it can be activated by hepatic cytochrome P450 enzymes
(Allen et al, 1976; Clarke and Waxman, 1989) to give 4-hydroxyi-
fosfamide (4-OHIF), which equilibrates with its tautomer, aldoIF,
both ofwhich are membrane permeable (Boyd et al, 1980; Sonawat
et al, 1990). The latter can be oxidized by aldehyde dehydrogenase
(ALDH) to give inactive carboxyifosfamide, a cause of chemo-
resistance, or it can decompose by 1-elimination to give isophos-
phoramide mustard (IPM), the primary alkylating agent. The IPM
has a PKa of4.75 and is membrane impermeable (Engle et al, 1979)
and therefore has to be formed intracellularly for its cytotoxic
action. Secondly, up to 50% ofIF can undergo spontaneous oxida-
tive dealkylation to give 2- or 3-dechloroethylifosfamide (2-DCI or
3-DCI) and chloroacetaldehyde, a compound with possible neuro-
toxic properties.
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IF and its metabolites are usually determined by classical
techniques (fluorimetry, mass spectrometry, chromatography) on
derivatized tissue extracts or body fluids (Wagner et al, 1981; Lind
et al, 1989; Boddy et al, 1993). More recently however, 31P-MRS
has also been used in vitro to follow the metabolism of two other
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Figure 1 Structure and metabolism of ifosfamide
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oxazaphosphorine cytostatics, cyclophosphamide and mafos-
famide, in cultured tumour cells (Boyd et al, 1980; Sonawat et al,
1990) and to analyse IF metabolities in body fluids from patients
(Martino et al, 1992; Gilard et al, 1993). With MRS, it is possible
to perform 'pharmacokinetics in situ' on the drug at its site of
action. The primary purpose of the present study was to use 31P-
MRS to monitor the pharmacokinetics ofIF in rat tumours in vivo,
with simultaneous monitoring of the endogenous phosphorus
metabolites (phosphocreatine (PCr), nucleoside triphosphate
(NTP), inorganic phosphate (Pa)) using a bolus dose previously
used in animals (Wiedemann et al, 1993). Doses similar to that
used in the present study are administered to patients, but as slow
infusions rather than a bolus (as reviewed by Kaijser et al, 1994).
Many tumours have poor vascularity and tend to be resistant to
radiotherapy and chemotherapy because of factors ranging from
intrinsic genetic resistance to extrinsic physiological factors (as
reviewed by Vaupel et al, 1989). As some studies have shown that
it is possible to enhance tumour blood flow and/or oxygenation by
carbogen (95% oxygen/5% carbon dioxide) breathing in animals
(Kruuv et al, 1967; Honess et al, 1995; Robinson et al, 1995) and
humans (Falk et al, 1992), the effects of carbogen breathing on IF
pharmacokinetics were also studied. Carbogen breathing has also
been shown to increase the efficacy ofradiotherapy (Rojas 1991).
Could the increase in blood flow - oxygenation observed with
carbogen breathing (thought to be duepartly to vasodilatory effects
of carbon dioxide), increase tumour delivery of the prodrug IF, or
ofits activated metabolites, andthereby enhance chemotherapeutic
action? Furthermore, the carbogen-induced increase in tumour
blood flow is rapidly reversed when air breathing is resumed
(Robinson et al, 1995), and thus it may be possible to trap IF inside
the tumour. To evaluate the efficacy of the IF, both with and
without carbogen breathing, tumour growth rate was measured.
As activation of IF to 4-OHIF occurs primarily in the liver and
carbogen breathing has been shown to increase relative tumour
perfusion, but not liver perfusion in RIF-1 tumour-bearing mice
(Honess et al, 1995), pharmacokinetic measurements in situ were
also performed on the liver with and without carbogen. To assess
the possibility that the prodrug IF itself might be directly toxic to
rat pituitary GH3 tumour cells, or might be converted by them to a
toxic metabolite, its effect on GH3 cells in vitro was also moni-
tored, using IF concentrations similar to those used in vivo.
METHODS
Ifosfamide (Mitoxana, ASTA Medica) was made up freshly each
day in normal saline, pH 7.2-7.4 and administered i.v. at a dose of
250 mg kg-', which is equivalent to 1.5 g m-2, using the surface
law formula (Benedict, 1934). If the animal was to recover from
the anaesthetic, MESNA (Uromitexan), a uroprotector was admin-
istered i.v. (150 mg kg-').
Cell culture
GH3 prolactinoma cells were grown in RPMI 1640 medium with
glutamine, supplemented with 10% fetal bovine serum, 5% horse
serum and 50 ,ug ml-' gentamycin at 37°C in a 5% carbon dioxide
atmosphere. Cell number was measured either directly using a
haemocytometer, or indirectly using 3-[4,5-dimethylthiazol-2-yl]-
2,5-diphenyltetrazolium bromide (MTT) in a colorimetric assay.
For the MTT assay, cells were seeded at 3300 cm-2 in 100-gl
aliquots, in quintuplet using 96-well plates. Twenty-four hours
later, IF, freshly prepared in Hanks' buffered salt solution (HBSS),
was diluted in growth medium and 100 gl added to wells to give
final concentrations of0.3-3 mm. After 24,48 and 72 h, MTT was
added (final concentration 0.45 mg ml-'), followed 4 h later by
sodium dodecyl sulphate (SDS) (final concentration 5%). After
>20 h, the plates were read at 540 nm using a microplate reader.
Results were expressed as a fraction ofcontrol (untreated cultures)
after conversion of absorbance readings to cell number, based
upon our standard curve for these cells. All cell culture materials
were purchased from Gibco BRL (Paisley, UK), apart from the
thiazolyl blue dye MTT and the SDS, which were obtained from
Sigma (Poole, UK).
Tumours
The GH3 prolactinomas were grown in the flanks of female
Wistar-Furth rats as described previously (Prysor-Jones and
Jenkins, 1981). The N-methyl-N-nitrosourea (MNU) mammary
tumours were chemically induced by three injections of MNU at
2-weekly intervals into Ludwig/Wistar/Olac rats, essentially as
described by Williams et al (1985). Tumour diameter was
measured with callipers, and the volume calculated using the
formula(ir6)d1d2d3.
31P-MRS
Animals were anaesthetized with pentobarbitone (40 mg kg-') and
maintained at 37°C. The tail vein was cannulated and an i.v. line
placed for administration of IF while the animal remained in the
magnet. 31P-MR spectra were obtained on a 4.7-T SISCO 200/300
spectrometer with a 20-mm, two-turn surface coil. Non-localized
spectra of tumours and livers, the latter from non-tumour-bearing
rats, were obtained using an adiabatic sincos pulse, TR of 3 s or 5
s and 60 or 120 acquisitions. Image-selected in vivo (ISIS)-local-
ized spectra (Ordidge et al, 1986) were obtained to confirm the
presence of IF in the tumour as distinct from the adjacent tissues.
However, the ISIS-localization is unsuitable for pharmacokinetic
studies because the spectra take too long to acquire. In the
carbogen experiments (n = 4), animals breathed carbogen from a
maskequipped with a scavenger, at a flow rate of 1.81 min-' for 10
min. IF was administered during the tenth minute of carbogen
breathing. Air was given before and afterthe carbogen. Mean arte-
rial blood pressure was measured using a Harvard Rat Tail BP
Monitor (Harvard Apparatus, Edenbridge, Kent, UK).
Measurements of pH and quantitation of spectra
pH was calculated from the chemical shift of(P, relative to a-NTP
at - 7.57 p.p.m. by the method of Prichard et al (1983). Spectra
were quantitated using VARPRO, a time domain non-linear least
squares method (van der Veen et al, 1988). To normalize the data,
the IF level was expressed as a ratio of IF to total phosphate
signals [i.e. a-, 3- and y-NTP, PCr, Pi and phosphomonoester
(PME)] in the spectra as total phosphate was unlikely to change
over the time course ofthe experiments.
Pharmacokinetic analysis
Curve fitting of the data (peak area vs time) was achieved using
the software package PCNONLIN (Lexington, KY, USA), which
provides a least squares estimate of the parameters in a non-linear
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Figure 3 Effect of i.v. IF (250 mg kg-') on NTP/P1 (, A) and pH (0, A) in
GH3 prolactinomas (0, 0) and mammary tumours (A, A). Data normalized to
pre-IF values of 1.32 ± 0.1 in GH3 prolactinomas and 2.09 ± 0.49 in
mammary tumours. Means ± s.e.m. for three or four animals, **P < 0.002,
*P < 0.03 (Student's t-test) compared with pre-IF value
RESULTS
Uptake of IF in GH3 and MNU-induced mammary
tumours in vivo
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Figure 2 Representative 31P-MR spectra 15 min
(A) a GH3 prolactinoma and (B) an MNU-induce
assignments are as follows: 1, ifosfamide; 2, phc
phosphodiesters; 5, phosphocreatine; 6, y-phosp
of NTP; 8, ,B-phosphate of NTP
Table 1 Effect of carbogen breathing on IF phari
prolactinoma and normal liver obtained from in vi
Tissue n Cmax
GH3 tumour 5 0.059 ± 0.002
GH3 tumour 4 0.094 ± 0.006a
+carbogen
Liver 4 0.063 ± 0.009
Liver 4 0.076 ± 0.002c
+carbogen
Results show the means ± sem, where Cm,, is th
expressed as a measure of IF/£P, t1,2 is half-life f
the area under (IF/YP) vstime curve. ap< 0.001,
compared with air breathing.
model. The best fit was obtained using a
with bolus input and first-order output usi
CT= D/V*exp(-K *r
where C = concentration (peak area), T= t
volume and K el = elimination rate. This yi
t,12 (= 0.693/K ) for each individual tumou
The 31P-MRS spectra of the tumours showed resonances from
-10 -20 -30 PME, Pi, phosphodiesters, PCr and from the cc-, ,B- and y-phos- phates ofNTP, all typical oftumour spectra (Figure 2). In addition,
a 3P-MR resonance, + 18 p.p.m. from PCr, which corresponded to
iafter i.v. IF (250 mg kg-') in IF, was detected in both the GH3 prolactinoma (Figure 2A) and the
d mammary tumour. Peak MNU-induced mammary tumour (Figure 2B) within a few
)sphomonoesters; 3, P,; 4, minutes of injection and was still visible 5-6 h later (not shown in
)hate of NTP; 7, a-phosphate
this IF signal in the tumour per se (results not shown). By
comparing the integral ofthe IF peak with that of ,-NTP, which is
known to correspond to about 1.4 ,umol g-' wet weight in this
macokinetics in the GH3 tumour type (van den Boogaart et al, 1995), the average concentra-
ivo 31P-MR spectra tion of IF in the tumour tissue over the first 2 h was calculated to
t (min) AUC
be 0.42 gmol g-' wet weight. (Corrections were made to account
for the small but significant initial decrease in NTP observed after
208 ± 25 17.9 ± 2.4 injection ofIF - see below.)
215 ± 27 28.9 ± 3.7b Time courses were pursued up to 6 h after injection and the
59 ± 10 5.1 ± 0.6 mean half-life ofIF (tl,2) was calculated to be 208 ± 25 min (n = 5)
71 ± 16 7.7 ± 1.6c in the prolactinoma (see also Table 1) and 165 ± 19 min (n = 3) in
the mammary tumour (data not shown). The time course showed
an initial rapid uptake followed by elimination of the drug over
e maximum peak area approximately 6 h (all time points not shown in Figure 5). No IF
or elimination and AUC is was detectable 24 h later.
bp< 0.05, cp> 0.15
Effect of IF on endogenous tumour phosphorus
metabolites
NTP/Pi decreased significantly (P < 0.002) to between 60% and
one-compartment model 85% of the original value in all the tumours within 30 min of IF
ing the equation: administration (Figure 3). There was also a concomitant fall in pH
of between 0.05-0.15 pH units in all tumours although it was
significant (P < 0.05) only in the GH3 prolactinomas. Parallel
.ime (min), D = dose, V= experiments were performed to test the hypothesis that these
ielded values ofCmax and changes were due to hypotension. In four out ofsix rats studied the
ir. mean arterial blood pressure fell to 70-90% of control within
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A Control rat til l Figure 6 Effect of carbogen breathing on IF pharmacokinetics [(IF/fP) vs l4
l l time] in normal liver measured by 31P-MRS. O, Control animals; *, animals
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Effects of carbogen breathing on IF pharmacokinetics
in GH3 prolactinomas
| | | Carbogen breathing by the rats bearing GH3 prolactinomas
30 20 10 0 -10 -20 -30 markedly increased IF uptake compared with controls breathing
p.p.m. air. Within 10 min of drug administration, the IF peak in the
tumour spectra after carbogen breathing (Figure 4B) was signifi-
Figure 4 Effect of carbogen breathing on the 31p spectrum of a GH3 cantly higher (P < 0.05) than in control IF-treated rats (Fig 4A). As
prolactinoma. (A) IF administered after 10 min breathing air. (B) IF
administered during tenth minute of breathing carbogen. The spectra were before, by comparing the integral of the IF peak with that of -
acquired 15 min after i.v. IF. Peak assignments as in Figure 2 NTP, the average concentration of IF in the tumour tissue over
the first 2 h (not shown in Figure 4) was calculated to be about
0.68 gmol g-' wet weight aftercarbogen breathing (compared with
0.11
- the air-breathing value of 0.42 glmol g-' wet weight). The differ-
0.10 4 r; ences were maintained throughout the time course (see Figure 5)
o. 09 - land
significant 150 min (P 0.01).
significant increase in the area under the (IF/YSP) vs time curve
0.08 (AUC) (P < 0.05) with carbogen breathing. However, the average
a. 0.07
- increase of about 50% in the initial IF concentration and in the
AUC was not accompanied by a significant change in the t112 for
r
;elimination (Table 1).
0.05 - W In rat liver, IF was also detected in vivo within a few minutes of
0.04
- injection (spectra not shown) with a t1/2 for elimination of 59 ± 10
9 g min. However, carbogen breathing did not significantly affect the
0.03 -1 pharmacokinetics of IF in the liver (Figure 6). There were no
0.02 . .
I significant differences either in t1/2 elimination rate (71 ± 16 min)
0 20 40 60 80 100 120 140 160 or in Cma in contrast to the significant difference in CmaX in the
Time (min) tumour (see Table 1).
Figure 5 Effect of carbogen breathing on IF pharmacokinetics [(IF/WP) vs
time] in GH3 prolactinomas measured by 3'P-MRS. 0, Control animals;
0, animals breathing carbogen. Means + s.e.m for three to five animals.
P < 0.01 (Student's t-test) for all time points except at 10 min (P = 0.02) and
120 min (P = 0.18)
10-15 min of 25 mg kg-' i.v. IF, and in three of those four rats it
recovered within 2 h (the fourth rat died without recovery of
normal blood pressure). While not fully conclusive, these results
suggest that the fall inNTP/P, and pH observed after i.v. bolus IF
could be due to drug-induced hypotension. Complete recovery to
control levels ofboth these parameters took between and 2 h.
Effects of carbogen breathing on the efficacy of IF
assessed by measurements of GH3 tumour growth
IF alone caused significant growth delay compared with untreated
tumours at day 12 (P < 0.02). Carbogen breathing in addition to IF
caused a further significant delay at all time points in GH3 tumour
growth between day 5 (P < 0.05) and day 12 (P < 0.01) compared
with the rats treated with IF alone (Figure 7). At day 13, untreated
tumours were 655 ± 75% ofthe size on day 0, whereas tumours of
the IF-treated rats, which had also breathed carbogen, showed
negligible growth 12 days after treatment.
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Figure 7 Effect of IF and carbogen breathing on GH3 tumour volumes. 0,
Control animals; 0, after i.v. IF (250 mg kg-'); A, after carbogen breathing;
and A, after IF plus carbogen breathing. Means ± s.e.m. Volume of tumours
at start of treatment was 2.89 ± 0.3 cm3 (n = 12)
Metabolites of IF
No active metabolites ofIF were seen in any ofthe in vivo tumour
spectra, although some in vivo liver spectra showed the presence
ofcarboxyifosfamide (data not shown).
Effect of IF on cultured GH3 cells
In an initial study using simple cell counting, incubation of IF (3
mM) with exponentially growing GH3 cells caused a significant
decrease in cell number at 24, 48 and 72 h. All subsequent studies
used the more sensitive MTT assay. Maximum growth inhibition
by IF was seen at 3 mM, whereas 0.3 mm had no significant
effect (Figure 8). The concentration of 3 mm reproducibly inhib-
ited cell proliferation yielding an IC50 at 72 h of 1.3 ± 0.2 mM
(mean±s.e.m., n=3). To test the possibility that the cytotoxicity of
IF was due to chemical breakdown in the medium, IF was preincu-
bated in cell culture medium (37°C) or in HBSS (4°C) for 48 h
before addition to the cells at a final concentration of 3 mm for 24
h. The percentage inhibition of growth observed for these two
treatments of 25.8±t0.3% and 29.2±0.5%, respectively, was actu-
ally less than that in which IF was added immediately to the cells
(44.4 ± 0.3%), demonstrating that cell-independent breakdown of
IF to cytotoxic metabolites was not significant.
DISCUSSION
Monitoring IF by 31P-MRS has several significant advantages over
chromatographic methods. It enables one to monitor the fate of a
drug in a living system without prior treatment, thus avoiding prob-
lems encountered with sampling, extraction, recovery and derivati-
zation. Furthermore, a complete time course can be followed in the
tumour of a single animal. The application ofMR spectroscopy to
IF metabolism has so far been reported in vitro, in studies ofbody
fluids (Martino et al, 1992; Gilard et al, 1993) and isolated cells
(Boyd et al, 1980; Sonowat et al, 1990), with one in vivo study
(Krems et al, 1994). In this study, we have shown that31P-MRS can
be used to monitor the pharmacokinetics of IF with simultaneous
observation of the endogenous phosphorus metabolites, without
*
-20 0 20 40 60 80
Time (h)
Figure 8. Effect of different concentrations of IF on GH3 cell proliferation in
vitro. After 24 h incubation of the cells, IF was either absent (U) or added to a
final concentration of 0.3 mm (0), 1 mm (A) or 3 mm (V). The absorbance of
the cell suspension was determined at 24-h intervals and converted to cell
number (for details see Methods). Results are expressed as means ± s.e.m.
of three experiments using normalized data. *P<0.01 (Fisher's ANOVA)
the need for serial biopsies. This has provided information on the
distribution and metabolism of the drug, while MRS in vitro has
given information on its excretion and metabolism. However, the
main limitation of 31P-MRS is its low sensitivity compared with
chromatographic methods. Indeed, no IF metabolites were detected
in vivo or in extracts ofthe two tumourtypes, probably because the
levels were below the detection threshold (about 0.2 mm in vivo
and 20gM in vitro depending on magnetic field strength). 4-OHIF,
the activated form ofIF, is extremely labile and difficult to measure
even by chromatographic techniques. Although carboxyifosfamide
(an inactive metabolite) was detected in some of the livers, it was
not detected in any tumours. There is some evidence that the pres-
ence ofcarboxy ifosfamide in tumours might indicate chemoresis-
tance to IF (Boal et al, 1994).
The intratumoral pharmacokinetics of IF were reproducibly
measured in both types oftumour and in the liver. While host liver
metabolism of IF is an important determinant of tumour response,
metabolism by the tumour itself may also be important in some
instances. Previous cultured-cell studies have used the activated
form ofIF, 4-OHIF, as activation ofIF occurs predominantly in the
liver. However, cytochrome P450 expressiorr has recently been
shown in malignant breast cancer cells (Murray et al, 1993), and
therefore it is possible that activation could take place in the cancer
cell. Our results using isolated GH3 cells showed cytotoxicity of
the parent drug (IF) in vitro, suggesting that the GH3 prolactinoma
cells may be either (1) expressing the P450 enzymes necessary for
the initial activation of IF or (2) sensitive to the parent drug per se.
The maximum IFconcentration observed in tumours with carbogen
breathing in vivo [on the assumption that the area under the f-NTP
is equivalent to 1.4 jmol g-' wet weight (van den Boogaart et al,
1995)] was 0.82 gmol g-' wet weight at 15 min after IF treatment,
similar in magnitude to the IC50 found in the cell culture experi-
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ments (1.3 mM). Furthermore, the concentration-response curve in
vitro was steep, with 0.3 mm having no effect. This suggests that
the 50% increase in tumour IF induced by carbogen breathing could
be biologically very significant.
The rationale for using carbogen inhalation to modify IF phar-
macokinetics and pharmacodynamics was also based on observa-
tions suggesting that the action of this prodrug could be enhanced
by the improvement in tumour blood flow induced by hyper-
thermia, both in cancer patients (Issels et al, 1990) and in human
tumour xenografts (Wiedemann et al, 1993). Wiedemann et al
showed that, with rising tumour temperature, the therapeutic effi-
cacy ofIF increased more steeply in vivo than in vitro and inferred
that this was due to an increase in tumour blood flow with hyper-
thermia. Carbon dioxide is a powerful vasodilator, hence carbogen
inhalation could mimic this effect by increasing blood flow to the
poorly perfused regions ofthe tumour (Honess et al, 1995), simul-
taneously improving tissue oxygen tension. This effect has been
demonstrated by large increases in the intensity of gradient
recalled echo magnetic resonance images (GRE MRI) of GH3
prolactinomas (Robinson et al, 1995), consistent with an increase
in both tumour blood flow and oxygenation, which return rapidly
to normal when carbogen is replaced by air breathing. Here, we
have shown by in vivo 3'P-MRS that carbogen breathing increases
the concentration of the prodrug, IF, within the tumour. This is
probably due to an increase in blood flow, and it is possible that it
may be accompanied by an increased delivery of the activated
form of IF, 4-hydroxyifosfamide. Alternatively, this tumour may
be able to activate IF in situ, as suggested by the in vitro studies,
but whatever the mechanism, more IF is taken up and retained by
the tumour (relative to that taken up by tumours of air-breathing
animals), and the chemotherapeutic index is increased.
The increase in the tumour concentration of IF with carbogen
breathing was not mirrored by an increase in liver IF. Our prelimi-
nary results show no evidence of GRE MRI signal intensity
increases in the liver, and therefore this was not unexpected. This
is also in agreement with the findings of Honess et al (1995), who
showed an increase in tumour, lung and skin perfusion caused by
carbogen breathing but no effect in normal liver, kidney, skeletal
muscle and spleen. Whether carbogen breathing causes increased
uptake of drug in the central nervous system and kidney, sites of
unwanted cytotoxity in patients (Goren et al, 1986 and Skinner et
al, 1990), is not known.
The ability to monitor in vivo the fate of a drug in a living
system may allow us to explore the fundamental mechanisms
underlying drug action as well as pharmacokinetic parameters that
could provide useful information on response to chemotherapy.
We have recently demonstrated, using GRE MRI, that carbogen
inhalation increases tumour blood flow and oxygenation in
patients (Taylor et al, 1996). The current study also suggests that
breathing carbogen may be useful in the clinic for selectively
increasing the uptake of chemotherapeutic agents into tumours,
thereby minimizing normal tissue toxicity and enhancing the effi-
cacy oftreatment.
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